AstraZeneca picks Oxford Biomedica to make potential COVID-19 vaccine

AstraZeneca has partnered with British cell therapy company Oxford Biomedica to make its experimental COVID-19 vaccine as the drugmaker looks to bolster its manufacturing capacity to produce one billion doses.